$13.74
11.80% today
Nasdaq, Apr 02, 10:03 pm CET
ISIN
US24823R1059
Symbol
DNLI
Sector
Industry

Denali Therapeutics Inc. Stock price

$13.74
-1.46 9.61% 1M
-15.29 52.67% 6M
-6.64 32.58% YTD
-5.64 29.10% 1Y
-21.45 60.95% 3Y
-3.70 21.22% 5Y
-7.71 35.94% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+1.45 11.80%
ISIN
US24823R1059
Symbol
DNLI
Sector
Industry

Key metrics

Market capitalization $1.78b
Enterprise Value $1.01b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
P/B ratio (TTM) P/B ratio 1.43
Revenue growth (TTM) Revenue growth -100.00%
Revenue (TTM) Revenue $0.00
EBIT (operating result TTM) EBIT $-501.88m
Free Cash Flow (TTM) Free Cash Flow $-363.61m
Cash position $832.33m
EPS (TTM) EPS $-2.58
P/E forward negative
P/S forward 54.44
EV/Sales forward 30.71
Short interest 8.45%
Show more

Is Denali Therapeutics Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,807 stocks worldwide.

Denali Therapeutics Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Denali Therapeutics Inc. forecast:

18x Buy
95%
1x Hold
5%

Analyst Opinions

19 Analysts have issued a Denali Therapeutics Inc. forecast:

Buy
95%
Hold
5%

Financial data from Denali Therapeutics Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs 7.80 7.80
48% 48%
-
-7.80 -7.80
102% 102%
-
- Selling and Administrative Expenses 90 90
22% 22%
-
- Research and Development Expense 396 396
6% 6%
-
-494 -494
172% 172%
-
- Depreciation and Amortization 7.80 7.80
48% 48%
-
EBIT (Operating Income) EBIT -502 -502
155% 155%
-
Net Profit -423 -423
191% 191%
-

In millions USD.

Don't miss a Thing! We will send you all news about Denali Therapeutics Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Denali Therapeutics Inc. Stock News

Neutral
GlobeNewsWire
about 9 hours ago
SOUTH SAN FRANCISCO, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the company's initiation of a rolling submission of a biologics license application (BLA) for accelerated approval of tividenofusp alfa for the treatment of Hunter syndrome (MPS II) has been received by the Center for Drug Evaluation and Research (CDER) of the U.S. Food ...
Positive
Seeking Alpha
13 days ago
Denali Therapeutics' stock has significantly dropped from $100 to $15 since 2021, but the company is now heavily derisked with promising product candidates nearing key milestones. Lead asset DNL310 shows strong biomarker data for Hunter syndrome, with plans for a BLA submission and accelerated approval by Q2 2025. The Biogen partnership for Parkinson's Disease asset DNL151 includes substantial ...
Neutral
GlobeNewsWire
about one month ago
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and year ended December 31, 2024, and provided business highlights.
More Denali Therapeutics Inc. News

Company Profile

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Head office United States
CEO Ryan Watts
Employees 422
Founded 2013
Website www.denalitherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today